Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EELS (Ethical, Economic, Legal & Social) Article

Pharmacogenomic-guided drug development: regulatory perspective

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Joubert PH et al . Euro J Clin Pharmacol 1988 34: 363–368

  2. Joubert PH, Brandt HD . Euro J Clin Pharmacol 1990 39: 183–186

  3. Kuivenhoven JA et al . N Engl J Med 1998 338: 86–93

    Article  CAS  Google Scholar 

  4. Narod SA et al . Lancet 2000 356: 1876–1881

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L J Lesko.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lesko, L., Woodcock, J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2, 20–24 (2002). https://doi.org/10.1038/sj.tpj.6500046

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500046

This article is cited by

Search

Quick links